# A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

> **NCT03324243** · PHASE2 · WITHDRAWN · sponsor: **Arog Pharmaceuticals, Inc.**

## Conditions studied

- Relapsed/Refractory FLT3-mutated AML

## Interventions

- **DRUG:** Crenolanib
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT03324243
- **Lead sponsor:** Arog Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-01
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn: Study halted prior to enrollment of first participant
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03324243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03324243, "A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03324243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*